Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 4, 2024

Primary Completion Date

July 14, 2025

Study Completion Date

August 30, 2025

Conditions

SARS-CoV-2 (COVID-19) Infection

Interventions

DRUG

Apo-Si-K170A-C76

Apo-Si-K170A-C76 is an small interfering RNA (siRNA) against SARS-CoV-2

DRUG

Placebo

5% glucose, 0.5% benzyl alcohol in RNase free water

Trial Locations (1)

HCRC Ein Karem, Jerusalem